Beta-Phellandrene

Beta-Phellandrene

SCHEMBL1306441

C=C1C=C[C@@H](C(C)C)CC1

nearest known ligand 0.31

Full drug profile on Sugi Atlas →

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
MET P08581 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Beta-Phellandrene SCHEMBL154149 1.00 MET (0.31) MET
Beta-Phellandrene SCHEMBL17629433 1.00 MET (0.31) MET
SCHEMBL25337903 0.86 CYP3A4 (0.34) MET
SCHEMBL23268474 0.83
SCHEMBL10413490 0.82
Germacrene D SCHEMBL113144 0.82 MET (0.47) MET
SCHEMBL11031845 0.82
SCHEMBL10412371 0.79
SCHEMBL10412372 0.79
Beta-Phellandrene SCHEMBL5011873 0.78 MEN1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12233147-B2 Method for treating keratin material HENKEL AG & CO. KGAA (DE) 2025-02-25 US disclosed
US-20240226034-A1 Use of Terpenoids and Salicylates as Anesthetics and Analgesics THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-07-11 US disclosed
WO-2022232231-A1 USE OF TERPENOIDS AND SALICYLATES AS ANESTHETICS, ANALGESICS, AND EUTHANASIA AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-11-03 WO disclosed
CN-108795773-B Musk mould strain and perfume prepared from same 贵州中烟工业有限责任公司 2022-09-20 CN disclosed
US-20220211601-A1 METHOD FOR TREATING KERATIN MATERIAL HENKEL AG & CO. KGAA (DE) 2022-07-07 US disclosed
EP-3946228-A1 METHOD FOR TREATING KERATIN MATERIAL Henkel AG & Co. KGaA (DE) 2022-02-09 EP disclosed
CN-113677314-A Increasing the stability of agents for treating keratin materials 汉高股份有限及两合公司 2021-11-19 CN disclosed
WO-2020200574-A1 METHOD FOR TREATING KERATIN MATERIAL HENKEL AG & CO. KGAA (DE) 2020-10-08 WO disclosed
US-8053587-B2 for mounting onto a circuit board semiconductor devices HENKEL CORPORATION (US) 2011-11-08 US disclosed
US-20080214840-A1 Reworkable thermosetting resin composition HENKEL CORPORATION (US) 2008-09-04 US disclosed
US-7012120-B2 Reworkable compositions of oxirane(s) or thirane(s)-containing resin and curing agent HENKEL CORPORATION (US) 2006-03-14 US disclosed
US-20050288458-A1 Reworkable thermosetting resin composition KLEMARCZYK PHILIP T 2005-12-29 US disclosed
US-20030073770-A1 Reworkable compositions of oxirane(s) or thirane(s)-containing resin and curing agent Henkel IP & Holding GmbH (DE) 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12233147-B2 Method for treating keratin material KRT18, CCNA1, CCNT1 MET 2310/4885
US-20220211601-A1 METHOD FOR TREATING KERATIN MATERIAL KRT18, CCNA1, CCNT1 MET 2310/4885
US-20080214840-A1 Reworkable thermosetting resin composition GSS, LSS, LRBA MET 4874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.